Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Neurocrine Biosciences Inc NBIX

Healthcare Biotechnology
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.


NDAQ:NBIX - Post by User

Neurocrine Biosciences Inc
<< Previous
 Bullboard Posts
User Avatar Image
(229)
•••
Post by whytestockson Aug 28, 2024 5:15pm
48 Views
Post# 36200161

Neurocrine Biosciences to Participate at Investor Conference

Neurocrine Biosciences to Participate at Investor Conference
Just In: $NBIX Neurocrine Biosciences to Participate at Investor Conferences in SeptemberNeurocrine Biosciences to Participate at Investor Conferences in September PR Newswire Morgan Stanley 22 nd Annual Global Healthcare Conference on September 4 in New York 2024 Wells Fargo Healthcare Conference on September 5 in Boston ...NBIX - Neurocrine Biosciences to Participate at Investor Conferences in September

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities